BXL 353

Drug Profile

BXL 353

Latest Information Update: 09 Dec 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioXell SpA; Roche
  • Developer BioXell SpA
  • Class Vitamin D analogues
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hyperparathyroidism

Most Recent Events

  • 09 Dec 2005 Discontinued - Preclinical for Hyperparathyroidism in Italy (unspecified route)
  • 31 Mar 2004 No development reported - Preclinical for Hyperparathyroidism in Italy (unspecified route)
  • 11 Jun 2002 Preclinical trials in Hyperparathyroidism in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top